Review

An update on palliative therapy in advanced prostate cancer
  • Kaan Özdedeli
  • Uğur Kuyumcuoğlu
Bull Urooncol 2014; 13: 8-14
İntravezikal tedavilere yardımcı yöntemler
  • Hüseyin Cihan Demirel
Bull Urooncol 2011; 10: 13-17
Treatment of small renal masses: Where we are in 2011
  • Mutlu Ateş
  • Mustafa Karalar
  • Engin Doğantekin
Bull Urooncol 2011; 10: 21-26
Is intravesical BCG treatment necessary and/or sufficient?
  • Sinan Ekici
  • Polat Türker
Bull Urooncol 2013; 12: 22-25
Comparing outcomes of external radiotherapy modalities for prostate cancer
  • Şefik İğdem
Bull Urooncol 2014; 13: 29-32
Should all patients with non-muscle invaziv bladder tumor receive postoperative early single dose intravesical chemotherapy?
  • Sümer Baltacı
  • Ömer Gülpınar
Bull Urooncol 2012; 11: 30-33
In which fields intermittent androgen deprivation therapy can be used in 2014?
  • Yasin Ceylan
  • Bu¨lent Gu¨nlu¨soy
Bull Urooncol 2014; 13: 33-36
Approach to the complications of intravesical therapy in bladder cancer
  • Turgay Gülecen
  • Cüneyd Özkürkçügil
Bull Urooncol 2012; 11: 34-40
Recent advancements in the targeted therapy of metastatic kidney cancer
  • Sertaç Yazıcı
  • Halil Kızılöz
  • Haluk Özen
Bull Urooncol 2011; 10: 41-51
Supportive treatment for patient receiving gemsitabine-cisplatine and suggestions for nursing
  • Yeter Kırdal
Bull Urooncol 2013; 12: 46-49
Can Bladder be Preserved with TURB + Chemotherapy instead of Radical Surgery (Can we Preserve the Bladder from Cancer)
  • Cavit Can
Bull Urooncol 2012; 11: 55-57
Could focal therapy in prostate cancer replace standard therapy in the future?
  • Saadettin Y. Eskiçorapçı
  • Cihan Toktaş
Bull Urooncol 2011; 10: 56-62
Risk Adaptive Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer
  • Elif Atağ
  • Aziz Karaoğlu
  • Ömer Küçük
Bull Urooncol 2017; 16: 57-62 DOI: 10.4274/uob.763
Neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer
  • Aziz Karaoğlu
  • Utku Oflazoğlu
  • Necla Demir
Bull Urooncol 2013; 12: 58-63
How should be follow-up strategy in stage 1 testicular tumor, are there any novelties?
  • Yakup Kordan
  • Mehmet Çağatay Çiçek
Bull Urooncol 2011; 10: 63-67
Neoadjuvant and adjuvant treatment modalities for prostate cancer
  • Erkan Erkan
  • Gökhan Toktaş
Bull Urooncol 2011; 10: 63-69
A New Era in Metastatic Prostate Cancer: “The Combination of Chemotherapy and Hormonal Treatment as Initial Treatment”
  • İlker Tinay
  • Levent Türkeri
Bull Urooncol 2016; 15: 65-68 DOI: 10.4274/uob.434
Management of post-chemotherapy residual masses in testicular tumor and surgical tecnique
  • Ferhat Ateş
  • Ömer Yılmaz
  • Kadir Vehbi Baykal
Bull Urooncol 2011; 10: 68-74
New chemotherapeutic approaches in testicular tumors
  • Arzu Yaren
  • Gamze Gököz Doğu
  • Serkan Değirmencioğlu
Bull Urooncol 2011; 10: 75-81
Treatment options in low-intermediate risk prostate cancer
  • Saadettin Yılmaz Eskiçorapçı
  • Deniz Bolat
Bull Urooncol 2013; 12: 80-85
Immunotherapy in prostate cancer
  • Murat Lekili
Bull Urooncol 2011; 10: 82-84
Are there any treatment option for metastatic prostate cancer refractory to docetaksel?
  • Yaşar Bedük
Bull Urooncol 2011; 10: 85-89
Radiotherapy in low and intermediate-risk prostate cancer
  • Deniz Yalman
Bull Urooncol 2013; 12: 86-91
Surgical treatment and/or radiotherapy in high risk prostate cancer
  • Fatih Bıçaklıoğlu
  • Cenk Acar
  • Sinan Sözen
Bull Urooncol 2013; 12: 97-101
Androgene suppression therapy in addition to radical radiotherapy in high risk prostate carcinoma
  • İlknur Bilkay Görken
Bull Urooncol 2013; 12: 102-105
The Approach to High Risk Bladder Cancers in The Absence of Bacillus Calmette Guérin: What should Be the Treatment and Follow Up?
  • Polat Türker
  • Levent Türkeri
Bull Urooncol 2014; 13: 103-108 DOI: 10.4274/UOB.09
Focal Therapy for Prostate Cancer: Current Status of HIFU
  • Tayyar Alp Özkan
  • Saadettin Eskiçorapçı
Bull Urooncol 2015; 14: 108-112 DOI: 10.4274/uob.321
The Prostatic Urethral Lift Method: A New Minimally Invasive Modality as an Alternative in the Treatment of Benign Prostatic Hyperplasia
  • Alpaslan Yüksel
  • Ali Tekin
Bull Urooncol 2016; 15: 119-122 DOI: 10.4274/uob.584
Current treatment approaches in locally advanced prostate cancer: a radiation oncologist perspective
  • Ömür Karakoyun Çelik
Bull Urooncol 2012; 11: 129-133
Management of recurrences after radiation therapy used for curative intent in prostate cancer
  • Yılören Tanıdır
  • Levent Türkeri
Bull Urooncol 2012; 11: 134-141
Salvage radical prostatectomy for locally recurrent prostate cancer following primary radiotherapy
  • Ali Cansu Bozacı
  • Sertaç Yazıcı
Bull Urooncol 2013; 12: 137-141
Adjuvant and Neoadjuvant Targeted Therapies in Locally Advanced Renal Cell Carcinoma
  • Ozan Bozkurt
  • Ömer Demir
Bull Urooncol 2014; 13: 139-145 DOI: 10.4274/uob.82
AUA/ASTRO 2013 Guidelines for Adjuvant and Salvage Radiation Therapy After Prostatectomy: What are the Yields and the Changes?
  • Deniz Yalman
Bull Urooncol 2015; 14: 144-149 DOI: 10.4274/uob.339
The role of surgery in renal cell carcinoma metastasis
  • Levent Mert Günay
  • Mehmet Cemil Uygur
Bull Urooncol 2013; 12: 147-150
‘Nanotechnology Applications’ in the Treatment of Prostate Cancer
  • Ali Furkan Batur
  • Kerem Gencer Kutman
  • Mustafa Suat Bolat
Bull Urooncol 2015; 14: 150-155 DOI: 10.4274/uob.375
Immunotherapy for the treatment of castration resistant prostate cancer: sipuleucel-T
  • Güven Aslan
Bull Urooncol 2012; 11: 156-158
Rising Psa After Radical Prostatectomy: Radiotherapy in High Risk Group: Early? Late?
  • Gül Alço
  • Sefik İğdem
Bull Urooncol 2015; 14: 161-164 DOI: 10.4274/uob.387
Postchemotherapy Retroperitoneal Lymph Node Dissection
  • Burak Çıtamak
  • Bülent Akdoğan
  • Mesut Altan
  • Haluk Özen
Bull Urooncol 2014; 13: 169-175 DOI: 10.4274/uob.138
Nursing interventions in patients receiving Taxan Chemotherapy
  • Yeter Kırdal
Bull Urooncol 2012; 11: 173-177
Most frequently seen side effects of targeted therapy: how to manage?
  • Önder Kara
  • Bülent Akdoğan
Bull Urooncol 2013; 12: 179-185
Current situation of the clinical stage I nonseminomatous germ cell testis tumour
  • Alim Koşar
  • Osman Ergün
Bull Urooncol 2012; 11: 181-184
Molecular Fundamentals of the Revolution in the Treatment of Renal Cell Carcinoma
  • Ece Konaç
  • Sinan Sözen
Bull Urooncol 2015; 14: 181-187 DOI: 10.4274/uob.312
Chemotherapy related adverse events in patients with testicular cancer
  • Özgür Tanrıverdi
  • Bülent Karabulut
Bull Urooncol 2012; 11: 196-200
The Diagnosis and Treatment of Retroperitoneal Mass
  • Ümit Gül
Bull Urooncol 2015; 14: 196-202 DOI: 10.4274/uob.419
Testicular cancers: developments in radiotherapy
  • Şefik İğdem
  • Gül Alço
Bull Urooncol 2013; 12: 210-213
Targeted Therapies in Advanced Renal Cell Cancer
  • Sinan Karaaslan
Bull Urooncol 2015; 14: 210-213 DOI: 10.4274/uob.396
Cytoreductive Nephrectomy in the Targeted Treatment Era
  • Özgür Yaycioglu
Bull Urooncol 2015; 14: 214-218 DOI: 10.4274/uob.435
Molecular Biology in Diagnosis and Treatment of Prostate Cancer
  • Ece Konaç
  • Sinan Sözen
Bull Urooncol 2014; 13: 228-235 DOI: 10.4274/uob.194
Phytotherapy in Benign Prostatic Hyperplasia
  • Mehmet Kaynar
  • Serdar Göktaş
Bull Urooncol 2014; 13: 236-240 DOI: 10.4274/uob.197
Neoadjuvant targeted therapy in renal cell carcinoma
  • Sertaç Yazıcı
  • Halil Kızılöz
  • Haluk Özen
Bull Urooncol 2012; 11: 240-245
Diagnostic and Prognostic Molecular Features of Urothelial Bladder Cancer and New Treatment Approaches
  • Zafer Küçükodacı
  • Kutsal Yörükoğlu
Bull Urooncol 2015; 14: 258-270 DOI: 10.4274/uob.366
The Effects of Hormonal Therapy on Quality of Life in Prostate Cancer
  • Yusuf Şenoğlu
  • Kamil Çam
Bull Urooncol 2015; 14: 317-320 DOI: 10.4274/uob.463
Quality of Life of Patients with Advanced/Metastatic Renal Cell Carcinoma During the Treatment Period with Targeted Drugs
  • Sinharib Çitgez
Bull Urooncol 2015; 14: 321-323 DOI: 10.4274/uob.460

Radiation Oncology

Radiation therapy for bladder cancer
  • Ömür Karakoyun Çelik
  • Fatma Sert
Bull Urooncol 2012; 11: 70-73
Possible problems and solutions after radiation therapy for prostate cancer
  • Serdar Özkök
Bull Urooncol 2011; 10: 98-102

General Urooncology

An approach to dermatological side effects of targeted therapies
  • Cemal Bilaç
  • Sedef Bayata
  • Serap Öztürkcan
Bull Urooncol 2012; 11: 295-300

About Journal

Forms

Useful Links

Applications